We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Phase IIa trial shows manageable tolerability and fibrosis reduction in JAK inhibitor-refractory myelofibrosis, indicating potential therapeutic benefit.
No takes yet. Share an insight, caveat, or question.
Schlenk et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: